Linden Advisors’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Linden Advisors’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-245,467	Closed	-$15.4K	–	574
2022 Q4	$15.4K	Hold	245,467	–	–	﹤0.01%	475
2022 Q3	$14K	Hold	245,467	–	–	﹤0.01%	623
2022 Q2	$16K	Hold	245,467	–	–	﹤0.01%	681
2022 Q1	$57K	Sell	245,467 -93,957	-28%	-$30K	﹤0.01%	646
2021 Q4	$214K	Hold	339,424	–	–	﹤0.01%	647
2021 Q3	$220K	Hold	339,424	–	–	﹤0.01%	569
2021 Q2	$294K	Buy	+339,424	New	+$236K	﹤0.01%	629

Linden Advisors's BIOTW Position: Q1 2023 in Review

Linden Advisors sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 245,467 shares — an estimated $15.4K sold.

Linden Advisors first reported a position in BIOTW in Q2 2021 and held it in 7 quarters. The position peaked at $294K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Linden Advisors reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Linden Advisors sold 245,467 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $15.4K.
Linden Advisors first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 7 quarters.
Linden Advisors's Biotech Acquisition Company Warrant position peaked at $294K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Linden Advisors's 13F filing for Q1 2023, filed 15 May 2023.